Stockreport

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]

Bolt Biotherapeutics, Inc.  (BOLT) 
PDF – BDC-3042 Phase 1 study successfully cleared safety assessments in the first three dose level cohorts – Cash balance of $128.6 million as of December 31, 2023, antic [Read more]